This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

In patients with type 2 diabetes with atherosclerotic combined dyslipidemia, the effect of atorvastatin and omega 3 combination on the progression of carotid intima media thickness and carotid artery plaque will be evaluated by 3D carotid ultrasound.

Inclusion Criteria:

• Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit

• Male or female of 20 years or over

• Mixed dyslipidemia under moderate-intensity statin: triglyceride ≥200 mg/dL, HDL-cholesterol ≤50 mg/dL, LDL-cholesterol ≥100 mg/dL

  • moderate-intensity statin: atorvastatin 10-20mg, rosuvastatin 5mg, simvastatin 20-40mg, pravastatin 40-80mg, lovastatin 40mg, fluvastatin XL 80mg, fluvastatin 40mg bid, pitavastatin 2-4mg

• Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm

• Asymptomatic patients without history of angina, myocardial infarction, or cerebral infarction

• Creatinine ≤1.8 mg/dL

Exclusion Criteria:

• Dyslipidemia which requires other therapy: triglyceride ≥500 mg/dL or LDL-cholesterol ≥190 mg/dL
• Uncontrolled hypertension: SBP >180 mmHg or DBP >110 mmHg
• Severe renal dysfunction: eGFR <30 mL/min/1.73m2
• AST/ALT >120/120 or chronic liver disease
• Pregnant or childbearing woman who does not have enough contraception
• Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months
• Usage of dyslipidemia therapy other than statin